Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction

Cancer Medicine

Volumn 4, Issue 7, 2015, Pages 1003-1015

  Kleibeuker, Esther A ^a   ten Hooven, Matthijs A ^a   Castricum, Kitty C ^a   Honeywell, Richard ^a   Griffioen, Arjan W ^a   Verheul, Henk M ^a   Slotman, Ben J ^a   Thijssen, Victor L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Combination therapy; Preclinical tumor model; Radiotherapy; Sunitinib

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADENOCARCINOMA CELL LINE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CHICKEN; CHORIOALLANTOIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG DOSE REDUCTION; EMBRYO; ESOPHAGEAL ADENOCARCINOMA; HT 29 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; MONOTHERAPY; NONHUMAN; OE19 CELL LINE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; NEOVASCULARIZATION, PATHOLOGIC; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RADIATION DOSAGE; RADIATION, IONIZING; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929842364     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.441     Document Type: Article

References (49)

1. Bernier, J., E. J. Hall, and A. Giaccia. 2004. Radiation oncology: a century of achievements. Nat. Rev. Cancer 4:737-747.
2. Delaney, G., S. Jacob, C. Featherstone, and M. Barton. 2005. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104:1129-1137.
3. Herman, J. M., A. T. Wild, H. Wang, P. T. Tran, K. J. Chang, G. E. Taylor, et al. 2013. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J. Clin. Oncol. 31:886-894.
4. Argiris, A., E. Pennella, and A. Koustenis, A. M. Hossain, C. K. Obasaju. 2013. Pemetrexed in head and neck cancer: A systematic review. Oral Oncol 49:492-501.
5. Stupp, R., W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-996.
6. Fan, Q. W., and W. A. Weiss. 2010. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr. Top. Microbiol. Immunol. 347:279-296.
7. Wu, L., L. Shao, M. Li, J. Zheng, J. Wang, W. Feng, et al. 2013. BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks. Radiat. Res. 179:160-170.
8. Amano, M., M. Suzuki, S. Andoh, H. Monzen, K. Terai, B. Williams, et al. 2007. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int. J. Clin. Oncol. 12:42-47.
9. Dings, R. P., M. Loren, H. Heun, E. McNiel, A. W. Griffioen, K. H. Mayo, et al. 2007. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13:3395-3402.
10. Mauceri, H. J., N. N. Hanna, M. A. Beckett, D. H. Gorski, M. J. Staba, K. A. Stellato, et al. 1998. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291.
11. Kleibeuker, E. A., A. W. Griffioen, H. M. Verheul, B. J. Slotman, and V. L. Thijssen. 2012. Combining angiogenesis inhibition and radiotherapy: A double-edged sword. Drug Resist. Updat. 15:173-182.
12. Mendel, D. B., A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, G. Li, et al. 2003. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9:327-337.
13. Schueneman, A. J., E. Himmelfarb, L. Geng, J. Tan, E. Donnelly, D. Mendel, et al. 2003. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63:4009-4016.
14. Zhang, H. P., K. Takayama, B. Su, X. D. Jiao, R. Li, and J. J. Wang. 2011. Effect of sunitinib combined with ionizing radiation on endothelial cells. J. Radiat. Res. 52:1-8.
15. Brooks, C., T. Sheu, K. Bridges, K. Mason, D. Kuban, P. Mathew, et al. 2012. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat. Oncol. 7:154.
16. Kao, J., S. Packer, H. L. Vu, M. E. Schwartz, M. W. Sung, R. G. Stock, et al. 2009. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 115:3571-3580.
17. Tong, C. C., E. C. Ko, M. W. Sung, J. A. Cesaretti, R. G. Stock, S. H. Packer, et al. 2012. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS ONE 7:e36979.
18. Staehler, M., N. Haseke, P. Nuhn, C. Tullmann, A. Karl, M. Siebels, et al. 2011. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int. 108:673-678.
19. Corn, P. G., D. Y. Song, E. Heath, J. Maier, R. Meyn, D. Kuban, et al. 2013. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int. J. Radiat. Oncol. Biol. Phys. 86:540-545.
20. Basille, D., M. Andrejak, H. Bentayeb, M. Kanaan, C. Fournier, E. Lecuyer, et al. 2010. Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy. Ann. Pharmacother. 44:383-386.
21. Hird, A. E., E. Chow, L. Ehrlich, L. Probyn, E. Sinclair, D. Yip, et al. 2008. Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature. J. Palliat. Med. 11:1156-1161.
22. Choi, Y. R., H. S. Han, O. J. Lee, S. N. Lim, M. J. Kim, M. H. Yeon, et al. 2012. Metastatic renal cell carcinoma in a supraclavicular lymph node with no known primary: a case report. Cancer Res. Treat 44:215-218.
23. van Beijnum, J. R., E. van der Linden, and A. W. Griffioen. 2008. Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp. Cell Res. 314:264-272.
24. Ruifrok, A. C., and D. A. Johnston. 2001. Quantification of histochemical staining by color deconvolution. Anal. Quant. Cytol. Histol. 23:291-299.
25. Honeywell, R., K. Yarzadah, E. Giovannetti, N. Losekoot, E. F. Smit, M. Walraven, et al. 2010. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878:1059-1068.
26. Weng, W.T., S. C. Huang, Y. L. Ma, H. H. Chan, S. W. Lin, J. C. Wu, et al. 2013. alpha-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway. Biochim. Biophys. Acta 1840:1850-1860.
27. Hong, J., Z. Zhang, W. Lv, M. Zhang, C. Chen, S. Yang, et al. 2013. Icaritin synergistically enhances the radiosensitivity of 4T1 breast cancer cells. PLoS ONE 8:e71347.
28. Shing, Y., J. Folkman, C. Haudenschild, D. Lund, R. Crum, and M. Klagsbrun. 1985. Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J. Cell. Biochem. 29:275-287.
29. Weiss, A., J. R. van Beijnum, D. Bonvin, P. Jichlinski, P. J. Dyson, A. W. Griffioen, et al. 2014. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J. Cell Mol. Med. 18:480-491.
30. Ribatti, D. 2012. Chicken chorioallantoic membrane angiogenesis model. Methods Mol. Biol. 843:47-57.
31. Imaizumi, N., Y. Monnier, M. Hegi, R. O. Mirimanoff, and C. Ruegg. 2010. Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. PLoS ONE 5:e11084.
32. Gerdes, J., H. Lemke, H. Baisch, H. H. Wacker, U. Schwab, and H. Stein. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1710-1715.
33. Takahashi, T., T. Nakano, K. Oka, and K. Ando. 2004. Transitional increase in growth fraction estimated by Ki-67 index after irradiation to human tumor in xenograft. Anticancer Res. 24:107-110.
34. Jing, C., J. Ning, and N. Yuanjie. 2012. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors. J. Cancer Res. Clin. Oncol. 138:2137-2143.
35. Zhu, Y., L. Xu, J. Zhang, X. Hu, Y. Liu, H. Yin, et al. 2013. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Sci. 104:1052-1061.
36. Gotink, K. J., H. J. Broxterman, M. Labots, R. R. de Haas, H. Dekker, R. J. Honeywell, et al. 2011. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17:7337-7346.
37. Kardamakis, D., C. Hadjimichael, P. Ginopoulos, and S. Papaioannou. 2004. Effects of paclitaxel in combination with ionizing radiation on angiogenesis in the chick embryo chorioallantoic membrane. A radiobiological study. Strahlenther. Onkol. 180:152-156.
38. Hatjikondi, O., P. Ravazoula, D. Kardamakis, J. Dimopoulos, and S. Papaioannou. 1996. In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity. Br. J. Cancer 74:1916-1923.
39. Karnabatidis, D., J. C. Dimopoulos, D. Siablis, D. Papazafiropoulos, C. P. Kalogeropoulou, and G. Nikiforidis. 2001. Quantification of the ionising radiation effect over angiogenesis in the chick embryo and its chorioallantoic membrane by computerised analysis of angiographic images. Acta Radiol. 42:333-338.
40. Bozec, A., A. Sudaka, N. Toussan, J. L. Fischel, M. C. Etienne-Grimaldi, and G. Milano. 2009. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann. Oncol. 20:1703-1707.
41. Zwolak, P., P. Jasinski, K. Terai, N. J. Gallus, M. E. Ericson, D. R. Clohisy, et al. 2008. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur. J. Cancer 44:2506-2517.
42. Casneuf, V. F., P. Demetter, T. Boterberg, L. Delrue, M. Peeters, and N. van Damme. 2009. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol. Rep. 22:105-113.
43. Chi, K. H., C. S. Liao, C. C. Chang, H. L. Ko, Y. W. Tsang, K. C. Yang, et al. 2010. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 78:188-193.
44. Conley, S. J., E. Gheordunescu, P. Kakarala, B. Newman, H. Korkaya, A. N. Heath, et al. 2012. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. USA 109:2784-2789.
45. Griffioen, A. W., L. A. Mans, A. M. de Graaf, P. Nowak-Sliwinska, C. L. de Hoog, T. A. de Jong, et al. 2012. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. 18:3961-3971.
46. Gaustad, J. V., T. G. Simonsen, M. N. Leinaas, and E. K. Rofstad. 2012. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer 12:388.
47. Casneuf, V. F., L. Delrue, N. van Damme, P. Demetter, P. Robert, C. Corot, et al. 2011. Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent. Radiat. Res. 175:10-20.
48. Hillman, G. G., V. Singh-Gupta, A. K. Al-Bashir, C. K. Yunker, M. C. Joiner, F. H. Sarkar, et al. 2011. Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl. Oncol. 4:110-121.
49. Sohal, D. P., J. M. Metz, W. Sun, B. J. Giantonio, J. P. Plastaras, G. Ginsberg, et al. 2013. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemother. Pharmacol. 71:1485-1491.